Long-term results in the treatment of acute nonlymphocytic leukemia: A pediatric oncology group study

✍ Scribed by Krischer, Jeffrey P. ;Steuber, C. Philip ;Vietti, Teresa J. ;Culbert, Steven J. ;Ragab, Abdelsalam H. ;Morgan, Samuel K. ;Berry, D. H. ;Hvizdala, Eva ;Thomas, Paul J. ;Land, Vita J. ;Castleberry, Robert P.

• Publisher: John Wiley and Sons
• Year: 1989
• Tongue: English
• Weight: 523 KB
• Volume: 17
• Category: Article
• ISSN: 0098-1532
• DOI: 10.1002/mpo.2950170509

✦ Synopsis

Complete remission (CR), 5-year remission duration (RD), and overall 5-year survivaf rates are 74%' 28%, and 25%, respectively, for previously untreated children with acute nonlymphocytic leukemia diagnosed between 1977 and 1981, following induction therapy with vincristine, doxorubicin and prednisone (VAP), consolidation therapy with 6-thioguanine, cytosine arabinoside (TA) and cyclophosphamideivincristine/cytosine arabinosidelprednisone (COAP), and maintenance therapy of alternating TA and COAP with or without VAP pulses. Approximately 20% are free of their disease for more than 5 years. High white blood cell counts (WBC) at diagnosis and M3 and M 6 morphology were associated with lower CR rates, while M5 morphology was associated with higher CR rates. Patients with MI morphology had shorter remission duration as compared to those with M 4 or M5 morphology. Low WBC and age between 2 and 10 years at diagnosis were associated with longer remission durations and survival. Patients with M 4 morphology also survived longer. The observed CR rates are comparable t o other studies initiated at the same time as this study but survival is less than those reported more recently. Low WBC at diagnosis and M4IM5 morphology may identify relatively favorable prognostic groups.